REG - Kromek Group PLC - Full Year 2025 Trading Update

KromekAnnouncement

Thu 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250508:nRSH7853Ha&default-theme=true

RNS Number : 7853H  Kromek Group PLC  08 May 2025

8 May 2025

 

Kromek Group plc

("Kromek" or the "Group")

 

Full Year 2025 Trading Update

Kromek to deliver revenue and profits ahead of market expectations

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the Advanced Imaging and CBRN Detection
segments, provides the following update on trading for the 12-month period
ended 30 April 2025.

 

FY 2025 has been a transformational year as Kromek made significant strategic
progress in both its Advanced Imaging and CBRN Detection segments.

 

In the Advanced Imaging segment, the Group signed a significant partnership
agreement with Siemens Healthineers and received the initial payment of $25.0
million out of a total of $37.5 million, with the remaining amount to be
received over the next four years. Consequently, revenue in the Advanced
Imaging segment grew significantly year-on-year.

 

In the second half of FY 2025, Kromek's CBRN Detection segment demonstrated a
clear recovery following a subdued start to the year. Revenues in H2 2025 were
more than double those of H1 2025, albeit from a low base, reflecting a strong
rebound in activity. During the year, the Group secured two milestone
agreements with UK Government entities for its nuclear security technologies.
Notably, Kromek was awarded and successfully delivered a contract from the UK
Ministry of Defence-one of the Group's key strategic customers. Additionally,
Kromek was selected as a supplier under a four-year UK Government framework
contract, with initial orders under this programme expected to commence in the
current financial year and continue throughout the contract duration. Beyond
the UK, Kromek continued to strengthen its global footprint, securing and
delivering multiple orders in the second half of FY 2025 from customers in the
US and Europe. The Group also continued to successfully deliver on the two
multi-year contracts from UK and US government agencies in its bio-security
technology area.

 

As a consequence of the positive financial impact of the partnership with
Siemens Healthineers, Kromek expects to report FY 2025 revenue ahead of market
expectations, of not less than £26 million, representing year-on-year growth
of at least 34%. Profit before tax is also expected to be slightly ahead of
market expectations. As at 30 April 2025, Group debt was £0.5 million
compared with £12.3 million at 31 October 2024, and the Group expects to
report net cash in line with market expectations.

 

Looking beyond FY 2025, Kromek anticipates delivering revenue growth for the
fifth consecutive year in FY 2026, while also maintaining profitability. This
positive outlook is underpinned by contracted revenue of approximately £20
million and a substantial near-term revenue pipeline.

 

Arnab Basu, Chief Executive Officer of Kromek, said: "FY 2025 has been a
transformative year for Kromek. Our landmark agreement with Siemens
Healthineers not only validates our leadership in Advanced Imaging technology
but has also significantly strengthened our financial position - enabling us
to substantially reduce debt and report pre-tax profitability for the first
time. While the CBRN Detection segment experienced a slower start, momentum
returned in the second half, supported by UK Government frameworks, US federal
contracts, and a healthy international sales pipeline. This gives us
confidence in sustainable growth for the year ahead.

 

"Looking forward, with contracted revenues of approximately £20 million, we
have strong visibility for FY 2026 and are well-positioned to deliver another
year of revenue growth, at least in line with market expectations, driving
long-term value for our shareholders."

 

For further information, please contact:

 

 Kromek Group plc
 Arnab Basu, CEO                                                        +44 (0)1740 626 060

 Paul Farquhar, CFO

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)        
 Geoff Nash/Giles Balleny/Seamus Fricker- Corporate Finance             +44 (0)20 7220 0500

 Tim Redfern- ECM

 Michael Johnson

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury/Henry Gamble                              +44 (0)20 4582 3500

 

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation and
solid-state readout technology, are primarily used to protect critical
infrastructure, events, personnel and urban environments from the threat of
'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFDLLBEELLBBD